This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shirtliff, M. E.
Right arrow Articles by Mader, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shirtliff, M. E.
Right arrow Articles by Mader, J. T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2002, p. 231-233, Vol. 46, No. 1
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.1.231-233.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Gatifloxacin Efficacy in Treatment of Experimental Methicillin-Sensitive Staphylococcus aureus-Induced Osteomyelitis in Rabbits

Mark E. Shirtliff,1,2* Jason H. Calhoun,3 and Jon T. Mader4,5

Center for Biofilm Engineering, Montana State University, Bozeman, Montana 59717-3980,1 Department of Microbiology and Immunology,2 Department of Orthopaedic Surgery, The University of Texas Medical Branch, Galveston, Texas 77555-1115,3 The Marine Biomedical Institute,4 Division of Infectious Diseases, Department of Internal Medicine5

Received 2 November 2000/ Returned for modification 16 January 2001/ Accepted 27 September 2001

The effectiveness of oral gatifloxacin was compared to that of standard parenteral antibiotic therapy (nafcillin) for the treatment of experimental methicillin-sensitive Staphylococcus aureus-induced osteomyelitis in a rabbit model. Gatifloxacin was as effective as nafcillin in clearing the infection. Therefore, oral gatifloxacin treatment of osteomyelitis may be an effective alternative to intravenous nafcillin treatment.

* Corresponding author. Mailing address: Center for Biofilm Engineering, 366 EPS Building, P.O. Box 173980, Montana State University, Bozeman, MT 59717-3980. Phone: (406) 994-4770. Fax: (406) 994-6098. E-mail: mshirtliff{at}erc.montana.edu.

Antimicrobial Agents and Chemotherapy, January 2002, p. 231-233, Vol. 46, No. 1
0066-4804/01/$04.00+0     DOI: 10.1128/AAC.46.1.231-233.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»